Bioage Labs, Inc.(BIOA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre Garnier as Board Chair RICHMOND, Calif.--BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechno ...